Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC
- 1.3k Downloads
Lung cancer is one of the most commonly reported cancers, and is known to be associated with a poor prognosis. The function of tumour-associated macrophages (TAMs) in lung cancer patients is multifaceted and the literature shows conflicting roles. (I) To analyze the Th1 and Th2 cytokine levels that contribute to the differentiation of M1 and M2 macrophage populations in the serum of patients with NSCLC versus non-cancer controls; and (II) To characterize the M1 and M2 macrophage populations within TAMs in different subtypes of NSCLC compared to non-tumour tissue. The Th1 and Th2 cytokine levels were analyzed in serum using the Bio-Plex assay. In addition, TAMs subsets from non-tumour and tumour tissues were analyzed using immunohistochemistry (IHC). The level of IL-1β, IL-4, IL-6 and IL-8 was found to be increased in the serum of patients with large cell carcinoma but not in other NSCLC subtypes compared to non-cancer controls. In addition, the expression of CD68 and M2 marker CD163 was found to be increased (P ≤ 0.0001) in all NSCLC subtypes compared to non-tumour tissues. In contrast, the expression of iNOS (M1 marker) was decreased in the tumour tissue of patients with adenocarcinoma (P ≤ 0.01) and squamous carcinoma (P ≤ 0.05) but not in large cell carcinoma compared to non-tumour tissue. The results of this study indicate that NSCLC might have the ability to alter phenotype within the lung tumour areas in the local environment (TAMs) but not in the bloodstream in the systemic environment (serum) except for large cell carcinoma.
KeywordsLung cancer Lung tissue Tumour-associated macrophages M1 macrophages M2 macrophages
This work was supported by the Institute for Breathing and Sleep project Grant and the School of Medical Sciences, RMIT University Grant Scheme.
Human Ethics approval was received from RMIT University Human Research Ethics Committee ASEHAPP 15-13 and the informed consent of all participants was obtained.
- 1.Shih J-Y, Yuan A, Chen JJ-W, Yang P-C (2006) Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2(3):101–106Google Scholar
- 10.Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM (2010) Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176(6):2972–2985. doi: 10.2353/ajpath.2010.090879 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7(10), e47045. doi: 10.1371/journal.pone.0047045 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(35):8959–8967. doi: 10.1200/jco.2005.01.4910 CrossRefGoogle Scholar
- 22.Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I, Ochiai A (2010) Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 5(10):1507–1515. doi: 10.1097/JTO.0b013e3181eba692 Google Scholar
- 23.Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632. doi: 10.1183/09031936.00129306 CrossRefPubMedGoogle Scholar
- 26.Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D (2003) Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer J Int Cancer 103(3):408–412. doi: 10.1002/ijc.10836 CrossRefGoogle Scholar
- 29.Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi: 10.1182/blood-2005-01-0428 CrossRefPubMedGoogle Scholar
- 31.Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3543–3551. doi: 10.1200/jco.2007.15.0375 CrossRefGoogle Scholar
- 32.Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, Gao J (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics 66(11):1879–1886. doi: 10.1590/S1807-59322011001100006 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer J Int Cancer 131(3):E227–E235. doi: 10.1002/ijc.27403 CrossRefGoogle Scholar
- 43.Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P (2010) Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy—association of interleukin-8 and VEGF with survival. Cytokine 50(1):30–36. doi: 10.1016/j.cyto.2009.11.017 CrossRefPubMedGoogle Scholar
- 46.Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387–408. doi: 10.1007/s10555-006-9004-4 CrossRefPubMedGoogle Scholar
- 48.Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E (2008) Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev 17(8):2180–2187. doi: 10.1158/1055-9965.EPI-07-2915 CrossRefPubMedGoogle Scholar
- 51.Pellegrini P, Contasta I, Del Beato T, Ciccone F, Berghella AM (2011) Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol 819724. doi: 10.1155/2011/819724